By Katherine Hamilton
Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial.
The stock was up 15% to $2.50 after the market close on Wednesday.
The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint.
The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients.
The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 22, 2025 17:24 ET (22:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.